August 2023 - Deep Dive

A better solution for Coeliac disease

Currently, the only available treatment for coeliac disease is to prescribe patients with a gluten-free diet. Gluten intolerance?in coeliac disease and?gluten sensitivity?in non-coeliac gluten sensitivity (NCGS) pose unmet clinical needs, even for subjects following this dietary regime.

The global gluten-free market size was estimated at $6.7b in 2022 and is expected to grow at a CAGR of 7.6% in the following decade. As more people try new diets, such as?paleo or keto, individuals who need or simply want?a gluten-free life, are becoming the key drivers of market growth. The world is witnessing a shift: consumers are adopting?healthier food and can now personalise their shopping experience to fit their unique nutritional demands through technological advancements?(Grand View Research, 2023).

While gluten-free products are becoming more readily available, factors such as contamination mean that while a product may not inherently contain gluten it may still produce a coeliac reaction. To make?matters worse gluten is often found in non-food products, such as dietary supplements, beauty and hygiene products, and even arts supplies.

What if there was a better solution? Discover?Nemysis Ltd.?the specialty pharmaceutical company focused on addressing?worldwide relevant nutritional deficiencies with particular attention not to damage the?patient’s microbiome, thus minimising a plethora of gastrointestinal side effects. E40?one of their flagship products, is a novel glutenase developed to break down partially digested glutens. E40?is an oral enzyme that?effectively breaks?down gluten with no immunogenic fragments exiting the stomach after its?digestion and maintaining up to 50% of its activity in the small intestine.